Progression
32
8
9
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.1%
1 terminated out of 32 trials
88.9%
+2.4% vs benchmark
9%
3 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (32)
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Liver Disease and Other Systemic Diseases
Effects of Progressive Relaxation Exercises
Research on Identifying and Treatment Prognosis of Chronic Rhinosinusitis Based on Image and Sequencing Data
The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Omitting CTV for Primary Tumor in LS-SCLC
The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer
Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.
Soluble B7-H3 as a Biomarker for Osteosarcoma
Laser Ablation After Stereotactic Radiosurgery
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation
Early Neurological Deterioration in Recent Small Subcortical Infarction
Intrapartum Translabial Ultrasonography Reliability
Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial
A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1